胆汁酸在胆汁淤积性肝损伤发病中的作用研究进展

doi:10.3969/j.issn.1672-5069.2020.06.041

摘要/Abstract

摘要： 胆汁酸由肝脏产生,是胆汁的主要成分之一。在胆汁分泌受阻时,血清和肝脏胆汁酸浓度上升,进而导致肝损害。尽管过去对于胆汁酸导致肝损害有过很多研究,但是其导致肝损害的分子机制目前仍存在争议。在本文中,我们总结了胆汁酸导致肝损伤发病机制的最新研究进展。在病理条件下,胆汁酸诱导肝细胞损害是通过处于应激条件下的肝细胞诱导炎症反应而发生的。本文主要聚焦胆汁酸如何诱导炎症因子的产生从而进一步诱导相关免疫细胞的聚集,以及基于对这些病理基础的认识,他们探讨了可能对胆汁淤积性肝损害有潜在治疗的新方法。

关键词: 胆汁淤积性肝损害, 胆汁酸, 炎症因子, 免疫细胞, 炎症信号通路, 胆管上皮细胞

Abstract: Objective Bile acid(BA) is synthesized in the liver and is the major component of bile. BAs accumulates in serum and liver when BAs secretion is impaired, which is followed by liver injury. The molecular mechanism of cholestasis has been extensively studied, however, it remains controversial. Recent studies showed that BAs might induce hepatocyte injury under pathological conditions, and the mechanism involved inflammatory response induced by stressed hepatocytes. In this article, we reviewed recent advances in the pathogenesis of liver injury induced by BAs and we focused on how BAs induce the activation of inflammatory cytokines that further induce the aggregation of immune cells. Based on these pathogenesis, we tentatively point out a number of novel treatments for cholestatic liver damage.

Key words: Cholestatic liver injury, Bile acids, Inflammatory cytokines, Immune cells, Signaling pathways, Cholangiocytes

何胜夫, 汪余勤. 胆汁酸在胆汁淤积性肝损伤发病中的作用研究进展[J]. 实用肝脏病杂志, 2020, 23(6): 919-922.

He Shengfu, Wang Yuqin. Role of bile acids in cholestatic liver injury[J]. Journal of Practical Hepatology, 2020, 23(6): 919-922.

参考文献

[1] 朱疆依,韩英.关于胆汁淤积性肝病诊断的几点探讨. 实用肝脏病杂志,2016,19:647-649
[2] 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志,2016;19:2-12
[3] Cao XX, Gao YQ, Zhang WH, et al.Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai. Chin J Hepatol,2015,23(8):569-573.
[4] Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury - what is the link? J Hepatol,2017,67:619-631.
[5] Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr,2018,18:71-87.
[6] Xiao Liu, Yan Wang. An overview of bile acid synthesis and its physiological and pathological functions. Hereditas (Beijing),2019,41(5):365-374.
[7] Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects of Med,2017,56:45-53.
[8] Virani S, Akers A, Stephenson K, et al. Comprehensive review of molecular mechanisms during cholestatic liver injury and cholangiocarcinoma. J Liver, 2018,7(3):321-325.
[9] Gujral JS, Farhood A, Bajt ML, et al. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology,2003,38:355-363.
[10] Ding L, Yang L, Wang Z, et al. Bile acid nuclear receptor fxr and digestive system diseases. Acta Pharm Sin B,2015,5:135-144.
[11] Marin JJ, Macias RI, Briz O, et al. Bile acids in physiology, pathology and pharmacology. Curr Drug Metab,2015,17:4-29.
[12] 周学谦, 陈文生. 胆汁淤积的分子机制与治疗靶点. 内科理论与实践,2018,13:388-393.
[13] Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (slc10a1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype. Hepatology,2015,61:260-267.
[14] Cai SY, Boyer JL. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm Cell Signal,2017,4:327-233.
[15] Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: A clear and present danger. Physio Rev,2010,90:1165-1194.
[16] Woolbright BL, Antoine DJ, Jenkins RE, et al. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol,2013,273:524-531.
[17] Woolbright BL, Dorko K, Antoine DJ, et al. Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. Toxicol Appl Pharmacol,2015,283:168-177.
[18] Woolbright BL, Jaeschke H. Inflammation and cell death during cholestasis: The evolving role of bile acids. Gene Expr,2019,19:215-228.
[19] Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. Am J Patho,2011,178:175-186.
[20] Woolbright BL, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol,2012,18:4985-4993.
[21] Cai SY, Boyer JL. The role of inflammation in the mechanisms of bile acid-induced liver damage. Dig Dis,2017,35:232-234.
[22] Cai SY, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight,2017,2:e90780.
[23] Luyendyk JP, Kassel KM, Allen K, et al. Fibrinogen deficiency increases liver injury and early growth response-1 (egr-1) expression in a model of chronic xenobiotic-induced cholestasis. Am J Patho,2011,178:1117-1125.
[24] Zhang Y, Hong JY, Rockwell CE, et al. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int,2012,32:58-69.
[25] Aranda JF, Reglero-Real N, Marcos-Ramiro B, et al. Myadm controls endothelial barrier function through erm-dependent regulation of icam-1 expression. Mol Bioln Cell,2013,24:483-494.
[26] Li M, Mennone A, Soroka CJ, et al. Na(+) /h(+) exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury. Hepatology, 2015,62:1227-1236.
[27] Murray PJ. Macrophage polarization. Annu Rev Physiol, 2017,79:541-566.
[28] Sato K, Hall C, Glaser S,et al. Pathogenesis of kupffer cells in cholestatic liver injury. Am J Patho, 2016,186:2238-2247.
[29] Calmus Y, Poupon R. Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases. Clin Res Hepatol Gastroenterol, 2014,38:550-556.
[30] Perino A, Schoonjans K. Tgr5 and immunometabolism: Insights from physiology and pharmacology. Trends Pharmacol Sci, 2015,36:847-857.
[31] Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol, 2017,66:1300-1312.
[32] Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies. Cell Mol Immunol, 2016,13:316-327.
[33] Duwaerts CC, Sun EP, Cheng CW, et al. Cross-activating invariant nkt cells and kupffer cells suppress cholestatic liver injury in a mouse model of biliary obstruction. PloS one,2013,8:e79702.
[34] Chuang YH, Lian ZX, Yang GX, et al. Natural killer t cells exacerbate liver injury in a transforming growth factor beta receptor ii dominant-negative mouse model of primary biliary cirrhosis. Hepatology ,2008,47:571-580.
[35] Cheng CW, Duwaerts CC, Rooijen N, et al. Nk cells suppress experimental cholestatic liver injury by an interleukin-6-mediated, kupffer cell-dependent mechanism. J Hepatol, 2011,54:746-752.